Results 201 to 210 of about 10,024 (235)

Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.

Clinical Infectious Diseases
BACKGROUND Immunocompromised patients, especially those receiving B-cell-depleting therapy (BCDT), remain at high risk for severe coronavirus disease 2019 (COVID-19). Although monoclonal antibodies showed benefit pre-Omicron, the real-world effectiveness
Cassandra Calabrese, Yifan Wang, A. Duggal, Shuaqui Huang, Yiying Fan, Shravan Kethireddy, G. Sacha, Leonard H. Calabrese, Xiaofeng Wang   +8 more
semanticscholar   +1 more source

The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo.

Virology
Oseltamivir, a neuraminidase inhibitor, is widely used in the clinic for treating influenza virus infections. However, suboptimal efficacy and risk of drug resistance development remain major challenges.
Xili Feng, Xuanye Yang, Xinyan Hu, Qianyun Liu, Yulin Ding, Xiaoan Cao, Zhongren Ma, Xiaoxia Ma   +7 more
semanticscholar   +1 more source

Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays.

Toxicological Sciences
In pharmaceutical drug development, animal tests are traditionally required to conduct comprehensive toxicity assessments before initiating human clinical trials.
Margaret Carrell Huntsman, Y. Marikawa
semanticscholar   +1 more source

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study

Respiratory Research
Few studies evaluated the effectiveness of COVID-19 antivirals specifically in the asthma population This study assessed short- and long-term effects of nirmatrelvir/ritonavir versus molnupiravir in asthma population. This is a retrospective cohort study
Guozhang Lin, Yuchen Wei, Zihao Guo, Huwen Wang, Kate Ching Ching Chan, Renee Wan Yi Chan, C. Hung, Xiaoting Jiang, Conglu Li, C. Yam, T. Chow, Yawen Wang, Shi Zhao, Kehang Li, Aimin Yang, C. Mok, David S. C. Hui, E. Yeoh, K. Chong   +18 more
semanticscholar   +1 more source

Characterization of the tautomeric equilibrium of molnupiravir, an antiviral for the treatment of COVID-19.

Journal of Pharmaceutical and Biomedical Analysis
A combined experimental NMR and DFT computational analysis of molnupiravir, an orally dosed antiviral effective for treatment of patients with COVID-19, determined that the molecule primarily exists as an oxime tautomer both in solution and in solid ...
Samantha A. Burgess, Xiao Wang, Dirk Stueber, Yunyi Wang, R. Cohen, Yu-hong Lam, Luca Iuzzolino, Mikhail Reibarkh   +7 more
semanticscholar   +1 more source

Immunosuppressants/molnupiravir

Reactions Weekly, 2023
openaire   +2 more sources

Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir

Free radical research
Molnupiravir is a prodrug of the antiviral ribonucleoside analogue N4-hydroxycytidine (NHC), for use in the treatment of coronavirus disease 2019 (COVID-19).
Yurie Mori, Rinya Yogo, Hatasu Kobayashi, H. Katsuzaki, Yuichiro Hirao, Shinya Kato, Hirokazu Kotani, Shosuke Kawanishi, M. Murata, S. Oikawa   +9 more
semanticscholar   +1 more source

Benzoyl Chloride Derivatization Coupled With Liquid Chromatography-Mass Spectrometry for the Simultaneous Quantification of Molnupiravir and Its Metabolite β-d-N4-hydroxycytidine in Human Plasma.

Journal of Separation Science
A sensitive and efficient method for simultaneous quantifying molnupiravir and its active metabolite β-d-N4-hydroxycytidine in human plasma was developed by combining chemical derivatization with liquid chromatography-tandem mass spectrometry.
Zhilong Yuan, Tao Ma, Lin Xia, Kaile Zheng, Mengdan Liu, Xiujuan Han, Wenjing Zhang, Zhuo Wang   +7 more
semanticscholar   +1 more source

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19

Clinical and Translational Science
Molnupiravir, an orally administered drug for the treatment of mild‐to‐moderate COVID‐19, is a prodrug of the ribonucleoside β‐D‐N4‐hydroxycytidine (NHC).
Akshita Chawla, R. Birger, Brian M. Maas, Youfang Cao, Hong Wan, Julie M. Strizki, Arthur Fridman, Amanda Paschke, Carisa De Anda, Wei Gao, Matthew L. Rizk, Wendy Painter, W. Holman, S. Sardella, George Painter, J. Stone   +15 more
semanticscholar   +1 more source

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources